Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...

Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...

Highlights:,Financial Performance:,Dimerix recorded a widened net loss, reflecting an increase compared to the previous reporting period.,Share Movement:,The company's stock experienced a decline over ...

Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.

In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...

Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney ...

As of February 5 at 10:48:56 AM GMT+11. Market Open.

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese ...

Investor reaction to PolyNovo's (ASX:PNV) half-year numbers shows how even seemingly minor earnings misses can result in a ...